Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nexeon completes manufacturing facility

24 Apr 2014 07:00

RNS Number : 3752F
Imperial Innovations Group plc
24 April 2014
 



24 April 2014

 

Imperial Innovations Group plc

 

Nexeon completes commissioning of manufacturing facility

Imperial Innovations plc (AIM: IVO, "Innovations", "the Group") is pleased to note that its portfolio company Nexeon Ltd, has completed the construction and commissioning of its process development and manufacturing facility at its headquarters in Oxfordshire.  

Nexeon, which is Innovations' second largest portfolio company by value, is developing silicon anode technology for the next generation of lithium ion (Li-ion) batteries. Silicon anodes offer benefits over conventional carbon anodes as they enable the development of lithium-ion cells with greater energy density. Nexeon has established a growing portfolio of patents covering materials and fabrication processes.

The company's new manufacturing plant is capable of producing over 20 tonnes of product a year, and has been built to handle a wide range of materials and reagents. In addition to the manufacturing capability, the new facility includes integrated laboratories for Process Development and Material Characterisation.

Russ Cummings, CEO of Imperial Innovations, said:

"Nexeon's new 20 tonne plant is highly versatile, with end-use applications spanning consumer electronic devices and electric vehicles. We look forward to the company sampling customers with products from this advanced manufacturing facility."

Enquiries:

 

Imperial Innovations Group Plc

020 3053 8834

Russ Cummings, Chief Executive Officer

Jon Davies, Director of Communications

 

Instinctif Partners

020 7457 2020

Adrian Duffield/Mel Toyne-Sewell

 

J.P. Morgan Cazenove

020 7742 4000

Michael Wentworth Stanley/Alec Pratt

 

Cenkos Securities

020 7397 8900

Andy Roberts/Christopher Golden

 

 

Notes to editors

 

About Imperial Innovations - www.imperialinnovations.co.uk 

 

Imperial Innovations creates, builds and invests in pioneering technologies developed from the academic research of the UK's four leading Universities. The Group supports scientists and entrepreneurs in the commercialisation of their ideas and intellectual property by leading the formation of new companies, providing facilities in the early stages, providing investment and encouraging co-investment to accelerate development, providing operational expertise and recruiting high-calibre management teams. It also runs an Incubator in London that is the initial home for many of its technology spin-outs.

Originally formed as the Technology Transfer office for Imperial College - a role it still carries out today, Innovations also invests in opportunities arising from intellectual property developed at, or associated with, Cambridge University, Oxford University and University College London. These are the top four research intensive universities in Europe with a research income of over £1.3 billion per annum.

Innovations invests in the most promising opportunities from whichever technology sector they arise, but has built particular expertise in the key sectors of: therapeutics, medtech, engineering and materials, and ICT.

Since listing in 2006, Innovations has invested a total of £160.9 million across its portfolio companies, which have raised collectively investment of over £750.0 million. Innovations' largest holding is in Circassia Pharmaceuticals, which listed on the London Stock Exchange main market in March 2014 with a market capitalisation of £581.0 million.

About Nexeon

Nexeon Ltd. ('Nexeon') is a battery materials company developing silicon anodes for the next generation of lithium-ion rechargeable batteries. A spin out of Imperial Innovations, Nexeon scientists have shown that producing silicon with particular morphologies makes it possible to overcome its limitations as an anode material. Batteries made with silicon anodes have significant performance advantages over their traditional equivalents.

Nexeon is based in Oxfordshire, and has a fully automated and instrumented pilot plant that closely represents a commercial manufacturing facility, and allows an accurate understanding of the processes and costs associated with making anode materials. The technology has been conceived with a 'drop in' approach, requiring the minimum of changes to an existing Li-ion battery manufacturing operation.

Nexeon has established a growing portfolio of patents covering materials and fabrication processes, and is building a store of available know-how which is available through licensing.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAXLDAASLEFF
Date   Source Headline
12th Dec 20123:02 pmRNSResult of AGM
16th Nov 20127:00 amRNSVeryan CE Mark approval for BioMimics 3D Stent
5th Nov 20127:00 amRNSPortfolio companies receive government funding
19th Oct 201210:00 amRNSGrant of share options
5th Oct 20127:00 amRNSFull year results
4th Oct 20127:00 amRNSCircassia initiates phase III trial
26th Sep 20127:00 amRNSPsiOxus commences clinical trial
20th Sep 201212:39 pmRNSNotice of Results
13th Sep 20123:25 pmRNSCircassia appoints Dr Brett Haumann as CMO
12th Sep 201211:35 amRNSAward Win
6th Sep 20127:00 amRNSInvestment in Cambridge technology company
1st Aug 20123:58 pmRNSDirector Dealings
23rd Jul 20127:00 amRNSInvestment in portfolio company
11th Jul 20122:50 pmRNSVeryan Medical appoints new COO and NEDs
9th Jul 20127:00 amRNS£22m funding round for PsiOxus Therapeutics
5th Jul 20125:20 pmRNSGrant of share options
27th Jun 20128:12 amRNSAbingdon Health acquires controlling stake
18th Jun 20127:00 amRNSInvestment in Oxford healthcare company
12th Jun 20127:00 amRNSInvestment in Cambridge technology company
31st May 20129:36 amRNSDirector/PDMR Shareholding
29th May 201210:05 amRNSPolytherics expands relationship with Pro Bono Bio
24th May 20127:00 amRNSDirector Dealings
1st May 20123:04 pmRNSDirector Dealings
23rd Apr 20127:00 amRNSHalf year results
26th Mar 20123:51 pmRNSNotice of Results
26th Mar 20127:00 amRNSInvestment in portfolio company
21st Mar 20127:00 amRNSDirectorate Change
8th Mar 20127:00 amRNSCircassia Phase II Clinical Trial Success
13th Feb 20127:00 amRNSInvestment in portfolio company
14th Dec 20115:27 pmRNSResult of AGM
6th Dec 20117:00 amRNSInvestment in new start-up
5th Oct 20117:00 amRNSFinal Results
27th Sep 20118:56 amRNSNotice of Results
7th Sep 20117:00 amRNSFurther investment in portfolio company
25th Aug 20117:00 amRNSInvestment in Cambridge company
22nd Aug 20117:00 amRNSInvestment in new company
3rd Aug 20117:00 amRNSInvestment in portfolio company
20th Jul 20117:00 amRNSInvestment in Stanmore
22nd Jun 20119:35 amRNSPortfolio company joint venture
19th Apr 20117:00 amRNSCircassia raises £60m
19th Apr 20117:00 amRNSHalf Yearly Report
30th Mar 201112:41 pmRNSNotice of Results
7th Feb 20116:00 pmRNSNotification of major interest in shares
3rd Feb 20118:16 amRNSDirectors' Dealings
27th Jan 20112:56 pmRNSNotification of major interest in shares
27th Jan 20112:51 pmRNSNotification of major interest in shares
26th Jan 20116:01 pmRNSNotification of major interest in shares
25th Jan 20116:03 pmRNSDirectors' Dealings
25th Jan 20115:40 pmRNSResults of Rump placing
24th Jan 20114:11 pmRNSVoting rights & share capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.